Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MicroRNA‑133b alleviates doxorubicin‑induced cardiomyocyte apoptosis and cardiac fibrosis by targeting PTBP1 and TAGLN2

11 May 2021

Abstract excerpt

Doxorubicin is one of the most important chemotherapeutic drugs for the treatment of malignant tumors, but the cardiotoxicity of doxorubicin severely limits its clinical application. Increasing numbers of microRNAs (miRNAs/miRs) have been found to be dysregulated in doxorubicin‑treated cardiomyocytes or animal hearts. The current study aimed to investigate the role of miR‑133b in doxorubicin‑induced cardiomyocyte...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiovascular Function and Risk Factors
Share to Chemotherapy-induced cardiotoxicity and mitigation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33982775
DOI: 10.3892/ijmm.2021.4958

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MicroRNA‑133b alleviates doxorubicin‑induced cardiomyocyte apoptosis and cardiac fibrosis by targeting PTBP1 and TAGLN2PMID 33982775Read ↗

Integrative transcriptomics and cell systems analyses reveal protective pathways controlled by Igfbp‐3 in anthracycline‐induced cardiotoxicitySemantic proximity Read ↗

MicroRNAs target the PI3K/Akt/p53 and the Sirt1/Nrf2 signaling pathways in doxorubicin‐induced cardiotoxicitySemantic proximity Read ↗

MicroRNAs in anthracycline cardiotoxicity: biomarkers, mechanisms, and therapeutic advancesSemantic proximity Read ↗

Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities: transcriptomic and epigenetic profilingSemantic proximity Read ↗

Different Mechanisms in Doxorubicin-induced Cardiomyopathy: Impact of BRCA1 and BRCA2 MutationsSemantic proximity Read ↗

Identification and Verification of the Effect of miR-143 on the Cardioprotective Role of Phosphocreatine in Doxorubicin- Induced Cardiotoxicity by Integrated Bioinformatics AnalysisSemantic proximity Read ↗

The anti-cancer drug doxorubicin induces substantial epigenetic changes in cultured cardiomyocytesSemantic proximity Read ↗

MicroRNA in the Diagnosis and Treatment of Doxorubicin-Induced CardiotoxicitySemantic proximity Read ↗

Integrated Omics Approach to Delineate the Mechanisms of Doxorubicin-Induced CardiotoxicitySemantic proximity Read ↗

WITHDRAWN: TGFB2-AS1 binding to MED1 promotes doxorubicin-induced cardiomyocyte apoptosis via BMP7 pathwaySemantic proximity Read ↗

Cardiomyocyte mitochondrial dynamic-related lncRNA 1 (CMDL-1) may serve as a potential therapeutic target in doxorubicin cardiotoxicitySemantic proximity Read ↗

Overexpression of hnRNPK and inhibition of cytoplasmic translocation ameliorate lipid disorder in doxorubicin-induced cardiomyopathy via PINK1/Parkin-mediated mitophagySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.